Tigecycline FDA Link

A tetracycline derivative that acts as a protein synthesis inhibitor. It is used as an antibacterial agent for the systemic treatment of complicated skin and intra-abdominal infections. It is also used for the treatment of community-acquired pneumonia.

Also Known As:

Tygacil; 9-(tert-Butylglycylamido)minocycline; GAR 936; GAR-936; TBG-MINO; GAR936; 2-Naphthacenecarboxamide, 4,7- bis(dimethylamino)- 9- ((2- ((1,1- dimethylethyl)amino)acetyl)amino)- 1,4,4a,5,5a,6,11,12a- octahydro- 3,10,12,12a- tetrahydroxy- 1,11- dioxo- , (4S,4aS,5aR,12aS)-

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthacenes
        Tetracyclines: 1162
        Tigecycline: 1386
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Tetracyclines: 1162
      - Tigecycline: 1386

G E Stein Selected Research

G E Stein Research Topics

Disease

Drug/Important Bio-Agent (IBA)